Pharma’s Physician Bailout
The pharmaceutical industry has been very generous in making payments to physicians. Last year (2010), for example, a mere dozen pharmaceutical companies paid $760 million to physicians and other health care providers for consulting, speaking, research and expenses. On average, how much do you think that comes to for every physician in the U.S.?
Pharma Marketing News Vol. 10, No. 3: 17 FEBRUARY 2011
Welcome to Volume 10, Issue #3 (17 FEBRUARY 2011) of Pharma Marketing News.
Vast Majority of Drug Ads in Leading Medical Journals Don’t Pass MDs’ Sniff Test!
A study led by Mount Sinai School of Medicine researchers of 192 pharmaceutical advertisements (83 full unique advertisements) in biomedical journals found that only 18 percent (15) were compliant with Food and Drug Administration (FDA) guidelines, and over half failed to quantify serious risks including death.
Most Credible Bad Ad Complaints are Submitted by Pharma
According to a Bad Ad Program 2010-2011 Year End Report just issued by the FDA, the program is a success despite the fact that ONLY 125 complaints were deemed worthy of
In Memory of Steve Jobs Will Novartis Sales Reps Really Embrace iPads?
David Epstein, head of Novartis Pharmaceuticals, said eighty percent of his company's sales reps will give up their PCs for iPads in 2012. Will they do it?
Physicians Favor Brands With a Compelling Adherence Program
This article summarizes the results of a survey of physicians designed to assess the value of various adherence solutions -- including HealthPrize -- and the potential of these solutions to influence physicians' prescribing behavior.
Pharma Marketing News Vol. 10, No. 16: 27 October 2011
Welcome to Volume 10, Issue #16 (27 OCTOBER 2011) of Pharma Marketing News.
Limiting Bias in Commercially Supported CME
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
Pharma Marketing News Vol. 10, No. 5: 10 MARCH 2011
Welcome to Volume 10, Issue #5 (10 MARCH 2011) of Pharma Marketing News.
Citizen Petition Likely to Delay FDA Social Media Guidance
Allergan, Eli Lilly, Johnson and Johnson, Novartis, Pfizer, Novo, and Sanofi-Aventis filed a 'citizen petition' with the FDA, urging the agency to 'establish comprehensive, clear and binding regulations to guide the industry' in communicating off-label drug information to physicians and payers. Although the words 'Internet' and 'Social Media' are not mentioned in the petition, it is likely to hold up social media guidelines regarding 'unsolicited requests' that were promised as the first in a series of FDA guidelines.
